DMRA Damora Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1800315 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,741.0%
TTM EPS YoY179.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-116.1%
ROA-107.4%
ROIC (approx.)-331.3%
Asset turnover—
Leverage & solvency
Liabilities / assets6.9%
Debt / equity0.00x
Current ratio14.80x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $26.88M | $6.40M |
| SG&A expense | $9.69M | $10.50M |
| Operating income | -$210.87M | -$22.26M |
| Pretax income | -$209.79M | -$21.40M |
| Income tax | $50,000 | $41,000 |
| Net income | -$209.84M | -$21.44M |
| EBITDA | -$210.85M | -$22.24M |
| EPS (basic) | 3.98 | -18.53 |
| EPS (diluted) | 3.98 | -18.53 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 1.36M | 1.16M |
| Banking | ||
| Net interest income | $1.17M | $844,000 |
| Balance sheet | ||
| Cash & equivalents | $257.62M | $14.18M |
| Short-term investments | $0 | — |
| Current assets | $260.42M | $16.84M |
| PP&E, net | $36,000 | $57,000 |
| Total assets | $260.53M | $17.13M |
| Current liabilities | $20.07M | $1.20M |
| Total liabilities | $20.15M | $1.30M |
| Shareholders' equity | $239.04M | $14.47M |
| Shares outstanding | 1.60M | 1.32M |
| Cash flow statement | ||
| Operating cash flow | -$6.73M | -$18.62M |
| Investing cash flow | -$17.37M | $11.65M |
| Financing cash flow | $266.84M | — |
| Depreciation & amortization | $22,000 | $21,000 |
| Stock-based compensation | $998,000 | $3.24M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.